Gyeonggi-do, South Korea

Geonmin Lee

USPTO Granted Patents = 1 

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Geonmin Lee: Innovator in Antibody Conjugation Technology

Introduction

Geonmin Lee is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that enhance antibody functionality. His innovative work has led to the filing of a patent that showcases his expertise and creativity in this area.

Latest Patents

Geonmin Lee holds a patent titled "Compound comprising Fc-binding unit, and conjugate prepared using same." This patent describes a compound that includes an Fc binding unit, which can be utilized to transfer a group of interest to an antibody in a position-specific manner. The patent also outlines a method for preparing an antibody conjugate that incorporates a group of interest, such as a reactive group, using the Fc binding unit. This innovation has the potential to advance therapeutic applications in medicine.

Career Highlights

Throughout his career, Geonmin Lee has worked with reputable organizations, including Abtis Co., Ltd. and Sungkyunkwan University. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to various research projects. His work has been instrumental in pushing the boundaries of antibody technology.

Collaborations

Geonmin Lee has collaborated with Yeong Soo Oh, a fellow researcher, to further explore the applications of his patented technology. Their partnership exemplifies the importance of teamwork in scientific research and innovation.

Conclusion

Geonmin Lee's contributions to the field of biotechnology, particularly through his patent on Fc-binding compounds, highlight his role as an innovator. His work not only advances scientific knowledge but also has the potential to impact therapeutic practices in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…